Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV (Euronext: GLPG) announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA). In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

"This trial marks the first time a Galapagos novel target candidate drug is tested in patients," said Onno van de Stolpe, CEO of Galapagos. "We are very proud of the high level of innovation that went into this program – from the cutting-edge science that led to this new target all the way to the innovative trial design, which will allow us to receive initial efficacy information for this candidate drug by the middle of next year."

Details of the Phase II clinical trial

The clinical Proof-of-Concept Phase II trial for GLPG0259 will involve 180 RA patients with insufficient response to the standard-of-care treatment, methotrexate (MTX), with the aim to evaluate the efficacy and safety of GLPG0259 in treating rheumatoid arthritis. Patients with moderate to severe rheumatoid arthritis will be divided into four groups, all continuing to receive a stable background of MTX, with three groups receiving a different once-daily dose of GLPG0259 and the fourth group receiving a placebo, for a period of 12 weeks. The primary endpoint will be the ACR20 response rate, the standard primary endpoint for RA clinical trials. Galapagos has received regulatory approvals to start the pan-European trial, with patient recruitment beginning next month. The trial has been designed to obtain initial efficacy data using the highest dose for the first 30 patients (20 receiving GLPG0259, 10 receiving placebo) in the first half of 2011. Based on this initial readout, Galapagos plans to complete the dose-finding component of the trial by the end of 2011.